Cartalax is classified as a peptide bioregulator, a category of ultrashort peptides studied for their ability to interact with DNA, histones, and chromatin components in laboratory systems.

Researchers study this peptide in controlled laboratory settings for its role in cartilage‑related pathways, including cellular signaling, extracellular‑matrix dynamics, and chondrocyte behavior within in‑vitro and preclinical connective‑tissue models

This is based on mechanistic modeling and in‑vitro assays, not clinical evidence.